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We were not prepared for the observation that the gastric bypass could make diabetesgo away. It’s not the way discoveries are made. Usually laboratories get the good
news first from test tubes, sometimes from animal experiments. Furthermore, entirely new
findings on the big diseases, like diabetes or cancer, just don’t come along very often.
The surprise came in 1982, in the early days of bariatric surgery, when our diabetic
morbidly obese patients were relieved, yes, fully relieved, from their insulin requirements
in a matter of days. We did not believe those initial glucose values, but our subsequent
long-term studies confirmed the initial observation. By the time our series reached 608
patients with a 95% follow-up for 16 years, the Greenville version of the gastric bypass
operation returned 83% of the patients with diabetes and 99% of those with impaired
glucose tolerance to euglycemia.1 Schauer and his group2 recently corroborated our
findings with an unusual congruence. In a study involving 1160 patients who underwent
gastric bypass with laparoscopy, they also found that 83% of the 240 diabetic patients
returned to euglycemia. They also confirmed our observation that the patients who did not
respond fully were older and had the diabetes longer than the successful group, suggesting
that early operation is indicated for the diabetic morbidly obese.
The operation produced more than just a return to normal glucose levels; it also
improved the comorbidities and reduced the mortality from the disease. During the same
time that we performed the gastric bypass on the 165 patients with diabetes, there were
another 76 patients who were scheduled for surgery but who, at the last minute, cancelled
their operations for personal reasons or because the insurance companies refused to pay
for the procedures. The 2 cohorts did not vary significantly in gender, age, body mass
index, or comorbidity. The mortality rates of the 2 groups, however, were sharply
different. In contrast to the patients who underwent the gastric bypass and had a total
mortality of 1% per year, the comparison group who did not have surgery died at the rate
of 4.5% per year (P 0.0001).3 In addition, the operation fully controlled the comorbidity
of morbid obesity, including asthma, gastroesophageal reflux disease, Pickwickian Syn-
drome, pseudotumor cerebri, and stress incontinence, as well as reduce mortality from
diabetes in the morbidly obese by 75%.
No other therapy has achieved such results. These studies reassure us that Type 2
diabetes mellitus is no longer a hopeless disease. These observations, however, are only
the beginning. The real challenge is to exploit these advances to learn how we can combat
type 2 diabetes mellitus, a disease that consumes 25 cents out of every health care dollar,
more effectively.
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How does the gastric bypass achieve this remarkable
remission? We have some clues. The decrease in food intake
certainly plays a role. Dietary management with a reduction
in calories, especially from carbohydrates, is a proven cor-
nerstone of diabetic therapy. In addition, the vertical banded
gastroplasty and gastric banding, 2 operations that depend
only on the restriction of intake, can induce significant ame-
lioration and, on some occasions, full remission of diabetes.
However, excessive food intake cannot explain the etiology
of diabetes nor can the reduction induced by the surgery
explain the full remission. Not all obese patients are diabetic
nor are all patients with diabetes obese.
What role does the gut play? And, of these roles, which
is the more important—the decrease in food intake or the
exclusion of food from part of the foregut? An ingenious
answer to this puzzle is provided by the elegant experiments
of Rubino and Marescaux4 in this issue of the Annals. They
performed a stomach-sparing version of the duodenal switch
in 10- to 12-week Goto-Kakizaki rats, a spontaneous nonobese
model of type 2 diabetes. Preoperative plasma glucose values of
159  47 mg/dL fell to 96.3  10.1 mg/dL (P  0.01). In
addition, the operation strikingly improved glucose tolerance,
inducing a greater than 40% reduction of the area under the
blood glucose concentration curve (P  0.001). These effects
were not seen in the sham-operated animals despite similar
operative time, same postoperative food intake rates, and no
significant difference in weight gain profile. In short, they
induced full remission of diabetes by an intestinal bypass with-
out a change in food intake or weight loss.
How might such a signaling system work? Imagine for
a minute that there is an engineer managing the islets. What
information would be needed to assure prompt delivery of
insulin, cessation of secretion when the need is gone, and
maintenance of inventory of the hormone? At the least,
prompt notice that food is being ingested, the composition of
the meal, quantity of the food, as well as the progress of the
food through the gut. Plasma glucose levels alone would not
suffice. These values have a lag time and they do not return
to normal levels quickly after the organism stops eating.
It is far more likely that this phase of the control of the
body’s energy use depends on a complex series of sequential,
integrated signals from a synchronized group of hormones
that are secreted by the gut and capable of influencing insulin
output and use. These include CKK, GIP, GLIp-1, and
ghrelin, among others. Additional fine tuning is probably
added from the fat stores, including leptin and adiponectin,
from muscle, with additional modulation from the hypothal-
amus, a complex system of feedback for a complex task.
So how can we tie these observations into a new
explanation of the pathophysiology of type 2 diabetes? Is the
traditional teaching correct that insulin resistance and mal-
function of the islets initiate the disease?
The new data, supported by the report in this issue of
the Annals, supports the concept that diabetes is the result of
overstimulation of the islets by one or several hormones pro-
duced in the foregut. Just as we have gastrinomas producing the
Zollinger-Ellison syndrome, there may be another set of foregut
endocrine cells that cause type 2 diabetes. The stimulation may
be caused by a single abnormal hormone, a chord of hormones,
or changed ratios between hormones. This impetus produces
hyperinsulinemia which, in turn, is followed by insulin resis-
tance. In this model, insulin resistance is not the cause but rather
a defensive mechanism of the cell.
The trick now is to identify the errant signals.
Bariatric surgery is far more than just another surgical
approach to obesity. It is a discipline that offers the first
successful therapies for a broad variety of illnesses ranging
from diabetes to pseudotumor cerebri. It opens entirely new
areas for basic science inquiry. It will also force us to learn
how to collect surgical data for large populations much more
efficiently and accurately so that we can compare the various
bariatric procedures, distinguish the indications for African-
Americans and Caucasians because these 2 groups respond
differently, and develop guidelines for approaches to pediat-
ric obesity. Perhaps, most important, it will provoke us to
pursue the cause of the obesity that has become a worldwide
epidemic.
We have a lot of work to do.
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